Oncopharmpod
HER2 Mutated NSCLC
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:14:59
- More information
Informações:
Synopsis
In light of trastuzumab deruxtecan's approval for HER-mutated NSCLC, it's worthwhile to look back at the history of HER-targeted therapy in NSCLC and why/how targeted HER-mutated disease will affect practice.
